Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Hyster-Yale Materials Handling (HY)
Consensus Price Target: $36.50 (23.9% implied return)
Playing a significant role in the development of the hydraulic lift truck, Hyster-Yale (NYSE: HY) designs, manufactures, and sells materials handling equipment to various sectors.
Why Are We Out on HY?
- Sales tumbled by 2% annually over the last two years, showing market trends are working against its favor during this cycle
- Projected sales decline of 6.4% over the next 12 months indicates demand will continue deteriorating
- Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 2.6% annually
At $29.46 per share, Hyster-Yale Materials Handling trades at 8.8x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than HY.
PacBio (PACB)
Consensus Price Target: $2.23 (35.6% implied return)
Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.
Why Is PACB Risky?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 4.5% annually over the last two years
- Cash-burning history and the downward spiral in its margin profile make us wonder if it has a viable business model
- EBITDA losses may force it to accept punitive lending terms or high-cost debt
PacBio’s stock price of $1.64 implies a valuation ratio of 3.1x forward price-to-sales. Check out our free in-depth research report to learn more about why PACB doesn’t pass our bar.
Corebridge Financial (CRBG)
Consensus Price Target: $39.54 (35.8% implied return)
Spun off from insurance giant AIG in 2022 to focus on the growing retirement market, Corebridge Financial (NYSE: CRBG) provides retirement solutions, annuities, life insurance, and institutional risk management products in the United States.
Why Do We Think Twice About CRBG?
- Net premiums earned contracted by 15.4% annually over the last two years, showing unfavorable market dynamics this cycle
- Efficiency has decreased over the last four years as its pre-tax profit margin fell by 22.4 percentage points
- Debt-to-equity ratio of 1.1× is concerningly high, indicating excessive leverage that could limit financial flexibility
Corebridge Financial is trading at $29.13 per share, or 1.2x forward P/B. Read our free research report to see why you should think twice about including CRBG in your portfolio.
Stocks We Like More
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
